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BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare but fatal tumour. Although most MPM patients show pleural effusion
at even the early stage, it is hard to diagnose as MPM at the early stage because a sensitive and reliable diagnostic marker for MPM has
not been found in plasma or pleural effusion.
METHODS: In this study, we investigated whether intelectin-1 was specifically contained in MPM cells and the pleural effusion of MPM
patient by immunohistochemistry, western blotting, and enzyme-linked immunosorbent assay.
RESULTS: Malignant pleural mesothelioma cell lines, but not lung adenocarcinoma cell lines, secreted intelectin-1. In immuno-
histochemistry, epithelioid-type MPMs, but neither pleura-invading lung adenocarcinomas nor reactive mesothelial cells near the lung
adenocarcinomas, were stained with anti-intelectin antibodies. Pleural effusion of MPM patients contained a higher concentration
of intelectin-1 than that of lung cancer patients.
CONCLUSION: These results suggest that detection of intelectin-1 may be useful for a differential diagnosis of epithelioid-type MPM in
immunohistochemistry and that a high concentration of intelectin-1 in pleural effusion can be used as a new marker for clinical
diagnosis of MPM.
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Malignant pleural mesothelioma (MPM) is a rare but fatal tumour.
Prognosis of MPM patients is very poor. The median survival
is only 9–12 months after chemotherapy or radical surgery
(Chailleux et al, 1988; Ruffie et al, 1989). Extrapleural pneumo-
nectomy that is followed by chemotherapy and radiotherapy
extends the median survival to 19 months (Sugarbaker et al, 1999).
Recently, it was reported that patients who completed neoadjuvant
pemetrexed plus cisplatin followed by extrapleural pneumo-
nectomy and radiation had a median survival of 29.1 months
and a 2-year survival rate of 61.2% (Krug et al, 2009). However,
the surgery is generally applicable to only some MPM patients at
the early stage.
It is hard to find MPM at the early stage for many reasons: it
often progresses to an advanced stage without specific symptoms;
radiographical diagnosis of MPM is difficult; and a sensitive and
reliable diagnostic marker for MPM has not been found. As MPM
is correlated with previous exposure to asbestos (Robinson and
Lake, 2005), the number of MPM victims is increasing relative to
the amount of asbestos used in the environment and would
likely reach its peak between 2015 and 2020 in Western Europe
(Peto et al, 1999) or in 2030 in Japan (Murayama et al, 2006).
Thus, diagnosis of MPM at the early stage is urgently required.
Although most MPM patients show pleural effusion at even the
early stage, a sensitive diagnostic marker for MPM has not been
found in the pleural effusion. It is often difficult on cytological
examination of the pleural effusion to even discriminate MPM
cells from invasive lung adenocarcinomas or reactive mesothelial
cells (Kitazume et al, 2000). For the differential diagnosis of MPM,
some immunocytochemical tests for cells in the pleural effusion or
some immunohistochemical tests for surgical pathologic speci-
mens are generally required. Calretinin, cytokeratin 5/6, glucose
transporter 1, mesothelin, and Wilm’s tumour gene product WT-1
have been reported as immunohistochemical positive markers
for epithelioid-type mesothelioma, which accounts for 50–80% of
MPM cases (Ordo ´n ˜ez, 2003; Kato et al, 2007). However, these
proteins are cytoplasmic or membrane-binding proteins and are
not predominantly secreted into the pleural effusion. Therefore,
these proteins undigested are difficult to detect in the pleural
effusion and could not be used as a diagnostic marker for MPM
in the pleural effusion.
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reported (Wali et al, 2005). Human intelectin-1 is a secretory
trimeric protein (Tsuji et al, 2007) and a host defence lectin that
binds to bacterial galactofuranose (Tsuji et al, 2009). mRNA
of intelectin-1 is expressed primarily in the heart or intestine
(Tsuji et al, 2001). Human intelectin-1 protein has been found in
plasma of normal healthy adults (Tsuji et al, 2009) and has not
been reported in other body fluids.
In this study, we analysed intelectin-1 produced by MPM cells
and measured intelectin-1 concentrations in pleural effusions or
plasmas of MPM patients. Epithelioid-type MPM cell lines, but not
lung adenocarcinoma cell lines, secreted trimeric intelectin-1.
In immunohistochemistry, epithelioid-type MPMs, but neither
pleura-invading lung adenocarcinomas nor reactive mesothelial
cells near the lung adenocarcinomas, were stained with anti-
intelectin antibodies. Pleural effusions of MPM patients contained
higher concentrations of intelectin-1 than those of lung cancer
patients and tuberculosis patients. In the pleural effusion, there
was no correlation between intelectin-1 and hyaluronic acid. These
results suggest that intelectin-1 in the pleural effusion may be
a proper diagnostic marker for MPM.
MATERIALS AND METHODS
All experimental protocols were approved by the ethical commi-
ttees of Kanagawa Cancer Center, Yokosuka-Kyosai Hospital, and
Kochi National Hospital. A written informed consent for this study
was obtained from each patient.
Antibodies and intelectins
Recombinant intelectins and affinity-purified rabbit anti-intelectin
polyclonal antibody (pAb) were prepared as described previously
(Tsuji et al, 2007). cDNA encoding the open reading frame
of human intelectin-2 was cloned from placental RNA by
reverse transcription–polymerase chain reaction (RT–PCR).
Anti-human intelectin-1 hybridomas were cloned from mouse
myeloma cell lines fused with lymph node cells of human
intelectin-1-immunised mice.
Cell lines
Human MPM cell lines, ACC-MESO-1 (RCB2292) and ACC-MESO-4
(RCB2293) (Usami et al, 2006); a human lung adenocarcinoma cell
line, A549 (RCB0098); and a human colon adenocarcinoma cell line,
Caco-2 (RCB0988), were obtained from RIKEN Cell Bank (Tsukuba,
Japan). Three human lung adenocarcinoma cell lines, ABC-1
(JCRB0815), RERF-LC-Ad2 (JCRB1021), and PC-3 (JCRB0077), were
obtained from JCRB Cell Bank (Osaka, Japan). Four human MPM cell
lines, NCI-H28 (CRL-5820), NCI-H2052 (CRL-5915), NCI-H2452
(CRL-5946), and MSTO-211H (CRL-2081), and a human prostate
adenocarcinoma cell line, DU145 (HTB-81), were obtained from
ATCC (Manassas, VA, USA). The human MPM cell lines – MEYK2
and MEYK4 – were established in this study from cells in pleural
effusions of Japanese MPM patients, Y2 and Y4 (Table 1), respectively.
Plasma and pleural effusion
Clinical information of the MPM samples is summarised in Table 1.
Plasma and pleural effusion were heparinised, collected as
centrifuged supernatants, and then stored at  801C. The MPM
samples were obtained from Kanagawa Cancer Center or Yokosuka-
Kyosai Hospital. Pleural effusions of non-MPM patients – 9 lung
adenocarcinomas, 2 lung small cell carcinomas, 1 lung large cell
carcinoma, 3 tuberculoses, and 10 bacterial pleuropneumonias
– were obtained from the Department of Clinical Research, Kochi
National Hospital. Normal healthy plasma was obtained from 19
healthy volunteers (9 men and 10 women; age range 25–69 years).
Western blotting
Plasma (0.5ml), pleural effusion (0.5ml), or galactose-Sepharose-
purified intelectin-1 from culture supernatant (2.5ml) was resolved
by 9% SDS–PAGE under non-reducing conditions and transferred
to a polyvinylidene difluoride membrane (Immobilon-P; Millipore,
Billerica, MA, USA). The membrane was blocked with 5% non-fat
milk and then treated with affinity-purified anti-intelectin pAb or
mAb. After washing, the membrane was treated with horseradish
peroxidase-conjugated donkey anti-rabbit IgG (GE Healthcare UK
Ltd, Buckinghamshire, UK) or horseradish peroxidase-conjugated
sheep anti-mouse IgG (GE Healthcare UK Ltd) and developed with
ECL advance (GE Healthcare UK Ltd). The membrane was reprobed
by incubating with 6 M guanidine HCl (pH 6.8), washed with water,
and re-blocked with 5% non-fat milk.
RT–PCR
Total RNA was purified with TRIzol Reagent (Invitrogen, Carlsbad,
CA, USA) from ACC-MESO-1 or ACC-MESO-4. RNA (1mg)
was reverse transcribed and amplified as cDNA with the OneStep
RT–PCR kit (Qiagen GmbH, Hilden, Germany) (0.6mM primers
(50-GTGGAGGGAGGGAGTGAAGGAG-30 and 50-GAGTCAATATG
ATTTATTGTTTTCTCTTCTG-30)a t9 4 1C for 30s, 561C for 30s,
and 721C for 1min). PCR products were resolved by 1.5% agarose
gel electrophoresis and stained by ethidium bromide. PCR
products were also sequenced directly.
Immunohistochemistry
Specimens were obtained from the Division of Pathology in
Kanagawa Cancer Center or Yokosuka-Kyosai Hospital. Pleural
Table 1 Clinical data of MPM patients and intelectin-1 concentration in their body fluids
Plasma
Pleural effusion
ID Sex/age Type Stage Asbestos exposure Intelectin-1 (ngml
 1) Intelectin-1 (ngml
 1) Hyaluronic acid (lgml
 1)
Y1 M/76 Epithelioid (PD) T3N2M0 + 135.8 83.6 27.0
Y2 M/74 Epithelioid T1bN0M0 + 118.6 3609.0 811.6
Y4 M/65 Epithelioid T3N0M0 + 420.0 9071.8 41.9
Y5 M/69 Epithelioid T1-2N0M0 + 320.3 537.0 90.6
Y6 M/61 Epithelioid T3 102.6 565.3 149.3
Y7 M/66 Epithelioid T3 92.0 7000.3 237.8
G1 M/68 Epithelioid T4N0M0 + 422.6 ND ND
G2 M/60 ND T4N0M0 ND 463.8 203.5
Abbreviations: MPM¼malignant pleural mesothelioma; ND¼not determined; PD¼poorly differentiated. The concentration of intelectin-1 or hyaluronic acid was measured by
ELISA as described in the Materials and Methods. Values represent the mean of duplicate determinations.
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paraffin-embedded thin-sliced sections. The section on glass slide
was deparaffinised and rehydrated with xylene and ethanol and
then heated at 1211C for 5min with an antigen retrieval buffer,
10mM Tris buffer (pH 9.0) containing 1mM ethylenediamine-
tetraacetic acid (EDTA). Endogenous peroxidase activity was
eliminated by incubating for 10min with 3% hydrogen peroxide.
After washing with phosphate-buffered saline, the section was
treated for 1h with 1.5mgml
 1 of affinity-purified anti-intelectin
pAb or mAb, 15:3G9. After washing with 20mM Tris-buffered
saline (pH 7.6) containing 0.05% Tween 20 (TBST), immuno-
reactivity was visualised by using Histofine Simple Stain MAX-PO
(R) or MAX-PO (M) (Nichirei Co., Tokyo, Japan) and 3,30-
diaminobenzidine according to the manufacturer’s instructions.
The section was finally counterstained with haematoxylin,
dehydrated, and mounted with Malinol medium (Muto Pure
Chemicals Co., Tokyo, Japan). Calretinin or thyroid transcription
factor-1 (TTF-1) was stained with anti-calretinin (rabbit anti-
calretinin mAb (SP13), Nichirei Co.) or anti-TTF-1 (mouse anti-
TTF-1 mAb (8G7G3/1), DAKO Japan Inc., Tokyo, Japan) according
to the manufacturer’s instructions, respectively.
Enzyme-linked immunosorbent assay (ELISA)
The concentration of intelectin-1 was measured by sandwich
ELISA. Plasma, pleural effusion, or culture supernatant was diluted
100 times, 100–1000 times, or 20 times with TBST plus 0.2%
bovine serum albumin (BSA), respectively. The intelectin-1 was
captured by affinity-purified anti-intelectin pAb immobilised
on 96-well plates and washed three times with TBST. The plates
were incubated with TBST plus 0.2% BSA containing mAb.
After washing, the plates were incubated with TBST plus 0.2%
BSA containing horseradish peroxidase-conjugated sheep anti-
mouse IgG (GE Healthcare UK Ltd), washed, and developed
with 3,30,5,50-tetramethylbenzidine (Thermo Fisher Scientific Inc.,
Rockford, IL, USA), and then the absorbance at 450nm was
determined. Recombinant human intelectin-1 for a standard was
purified from human intelectin-1-transfected RK-13 cells using
galactose-Sepharose (Tsuji et al, 2001). The concentration of
intelectin-1 standard was estimated on the basis of the absorbance
at 280nm and the predicted extinction coefficient (Mach et al,
1992) of human intelectin-1.
The concentration of hyaluronic acid in pleural effusion was
measured using Hyaluronan Assay Kit (Seikagaku Biobusiness Co.,
Tokyo, Japan).
RESULTS
Antibodies against human intelectins
The antibodies used in this study are summarised in Figure 1 and
Supplementary Table 1. The mAbs – 1:1A8, 2:1C3, 3:1D7, 10:2D11,
and 15:3G9 – that recognised the N-terminus of human intelectin-1
(Supplementary Table 1) detected non-reducing intelectin-1 on
western blotting (Figure 1A). Two mAbs, 5:1H11 and 9:2D2, that
bound to the C-terminus of intelectin-1 (Supplementary Table 1)
weakly bound to non-reducing intelectin-1 on western blotting
(Figure 1A). These mAbs, except for 12:2G2, did not recognise
intelectin-2, which is another homologue in humans (Supplemen-
tary Table 1). Affinity-purified anti-intelectin pAb bound to both
the N-terminus and the C-terminus of intelectin-1 or intelectin-2
because the pAb detected reducing or non-reducing intelectin-1
and intelectin-2 (Figure 1B) and captured these intelectins
(Supplementary Table 1).
Human intelectin-1 was a disulphide-linked trimer with
glycosylation, as described in a previous report (Tsuji et al,
2007). On the other hand, intelectin-2 migrated to molecular size
corresponding to a monomer under the non-reducing conditions
(Figure 1B). A single 34kDa band of intelectin-2, which was
equivalent to molecular weight without glycosylation, was shown
under the reducing conditions, indicating that three bands of non-
reducing intelectin-2 were derived from unequal disulphide-linked
formation of intelectin-2 (Figure 1B). These results suggest that
both intelectin-1 and intelectin-2 are detectable and distinguish-
able by western blotting using pAb.
Secretion of intelectin-1 from mesothelioma cells
Anti-intelectin-1 mAbs, 9:2D2 or 10:2D11, recognised an epitope
in the C-terminus or N-terminus of human intelectin-1, respec-
tively (Supplementary Table 1). As shown in Figure 2A, three
human mesothelioma cell lines – ACC-MESO-1, ACC-MESO-4,
and MEYK4 – secreted 120kDa trimeric intelectin-1 recognised
by these mAbs into the culture supernatant. In contrast, four
lung adenocarcinomas (ABC-1, RERF-LC-Ad-2, PC-3, and A549), a
colon adenocarcinoma (Caco-2), and a prostate adenocarcinoma
(DU145) did not express intelectin-1. A mAb, 15:3G9, recognised
an epitope in the N-terminus of human intelectin-1 (Supplemen-
tary Table 1) and sensitively detected reducing or non-reducing
intelectin-1 on western blotting (Figure 1A). A small amount
of intelectin-1 secreted from MEYK2 was detected by 15:3G9
(Figure 2A). The intelectin-1 of ACC-MESO-4 or MEYK4 was also
detected by this mAb, but intelectin-1 of ACC-MESO-1 was not.
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Figure 1 Western blotting using anti-intelectin antibodies. (A) Recom-
binant human intelectin-1 (5ng per lane) was resolved by SDS–PAGE
under the non-reducing (NR) or the reducing (R) conditions and detected
by western blotting using mAb or affinity-purified anti-intelectin pAb.
(B) Recombinant intelectin-1 (rITLN1) and recombinant intelectin-2
(rITLN2) were purified with galactose-Sepharose from culture supernatant
of transiently intelectin-transfected RK-13 cells. Serum intelectin-1 (Serum
ITLN1) was purified from the serum of healthy human donors. The samples
were detected by western blotting using anti-intelectin pAb, as described
in the Materials and Methods.
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15:3G9. There was no difference between the intelectin-1 mRNA of
ACC-MESO-1 and that of ACC-MESO-4; both cell lines transcribed
a similar amount of intelectin-1 mRNA (Figure 2B) and each
intelectin-1 had the same single-nucleotide polymorphisms:
A48G (silent mutation), T258C (silent mutation), and A326T
(D109V). Mesothelioma cell lines derived from epithelioid-type
MPM – ACC-MESO-1, ACC-MESO-4, MEYK2, MEYK4, NCI-H28,
NCI-H2052, and NCI-2452 – secreted intelectin-1 detected by anti-
intelectin-1 pAb, yet MSTO-211H derived from lung-metastatic
site of biphasic MPM did not secrete intelectin-1 (Figure 2C).
These results suggest that epithelioid-like mesothelioma cell lines,
but not the non-mesothelioma lines, secrete trimeric intelectin-1.
In addition, the results also indicate that the intelectin-1 of
ACC-MESO-1 lacks an epitope of 15:3G9, although the coding
sequence of itln-1 gene of ACC-MESO-1 is the same as that of
ACC-MESO-4.
Immunohistochemistry of MPM
The results of MPM immunohistochemistry are shown in Figure 3.
Intelectin-1 was detected in the cytoplasm but not in the nucleus
(Figure 3). Epithelioid-type MPMs were immunostained with anti-
intelectin antibodies, 15:3G9 or pAb, as well as antibody against
calretinin, a typical positive marker for epithelioid-type meso-
thelioma (Figure 3Aa–Ad). All tested epithelioid-type MPMs
were stained with anti-intelectin antibodies; well-differentiated
epithelioid-type mesotheliomas near a pleura surface tended to
express intelectin-1 (Figure 3A), whereas a small number of poorly
differentiated epithelioid-type mesothelioma produced intelectin-1
(Figure 3Ag). Pleura surface mesothelioma cells expressed both
calretinin (Figure 3Ab) and intelectin-1 (Figure 3Ac and Ba);
in contrast, reactive mesothelial cells on a lung adenocarcinoma-
invaded pleura expressed calretinin (Figure 3Bb) but not
intelectin-1 (Figure 3Bc). The pleura-invading lung adenocarcino-
ma, which expressed TTF-1 (Figure 3Bd, arrow), was not stained
with both anti-calretinin (Figure 3Bb, arrow) and anti-intelectin
(Figure 3Bc, arrow). In specimens of eight pleuritis patients with
lung adenocarcinoma, no cell expressed intelectin-1 (data not
shown). In a biphasic-type MPM patient, epithelioid-like meso-
thelioma cells (Figure 3C, left side) but not sarcomatoid-like
cells (Figure 3C, right side) expressed intelectin-1. These
results suggest that epithelioid-type MPM specifically expresses
intelectin-1 protein. The detection of intelectin-1 expression in a
pleural biopsy sample may be useful for differential diagnosis of
epithelioid-type MPM, because invasive lung adenocarcinomas
and calretinin-positive reactive mesothelial cells, which often
cause a difficult diagnosis of MPM, did not express intelectin-1.
Because intelectin-1 mRNA is expressed in normal intestines
(Tsuji et al, 2001), we also investigated expression of intelectin-1
in colon cancer. Intelectin-1 was detected in the cytoplasm of
normal colonic goblet cells (Figure 3Da) but not that of colon
adenocarcinomas (Figure 3Db). In seven patients, colon carcino-
mas did not express intelectin-1 (data not shown). Thus, colon
cancer would not increase the amount of intelectin-1 in a body.
Intelectin-1 in plasma and pleural effusion
Trimeric intelectin-1 (120kDa) was detected in plasma (Figure 4A)
and pleural effusion (Figure 4B) of all MPM patients on western
blotting. As shown in Figure 4, most pleural effusions contained
larger amounts of intelectin-1 than plasma. The amount of
intelectin-1 in the plasma of MPM patients was inconsistent and
did not correlate with that of the pleural effusion. There was no
obvious shift in the electrophoretic mobility of trimeric intelectin-
1 of MPM patients compared with plasma intelectin-1 of normal
healthy donors. A band of monomeric intelectin (30kDa) was not
detected with pAb in plasma (Figure 4A), whereas it was detected
in pleural effusions of some MPM patients (Figure 4B, Y2, Y4,
and Y7) with pAb but not 15:3G9. These results suggested that the
pleural effusions of some MPM patients contained small amounts
of intelectin-2 with intelectin-1.
The concentration of intelectin-1 in plasmas and pleural
effusions is shown in Figure 5 and Table 1. The plasmas of three
MPM patients (Y4, Y5, and G1) contained intelectin-1 at higher
concentrations than those of normal healthy donors (Figure 5A
and Table 1). However, there was little difference between the
mean concentration of plasma intelectin-1 in MPM patients and
that in healthy donors (Figure 5A). On clinical diagnosis, it is
important that the pleural effusion of MPM is distinguished from
that of lung cancer or tuberculosis. The pleural effusions of
epithelioid-type MPM patients were apt to contain higher concen-
trations of intelectin-1 than those of lung cancer or tuberculosis
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Figure 2 Production of intelectin-1 in MPM cell lines. (A) Intelectin-1
was purified with galactose-Sepharose from 3 days of culture supernatant
containing 10% fetal bovine serum and was detected as a single 120kDa
band by non-reducing western blotting. Intelectin-1-transfected RK-13 cells
(ITLN-RK13) were cultured in medium containing 5% fetal bovine serum.
Results were obtained by reprobing and reblotting of an identical
membrane as described in the Materials and Methods. Serum intelectin-1
(Serum ITLN1) was prepared from the serum of healthy human donor.
(B) Intelectin-1 mRNAs of two MPM cell lines were compared using
semiquantitative RT–PCR. A sample without RNA was used as a negative
control (NC). (C) Intelectin-1 was purified with galactose-Sepharose from
5 days of culture supernatant containing 10% fetal bovine serum and
was detected by non-reducing western blotting using affinity-purified
anti-intelectin pAb.
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spatients (Figure 5B and Table 1). Half of the pleural effusions of
MPM patients (Y2, Y4, and Y7), but not patients with other
diseases, contained 43000ngml
 1 of intelectin-1. Most pleural
effusions of patients with other diseases contained o1000ngml
 1
of intelectin-1 (Figure 5B). A high concentration of hyaluronic acid
(4100mgml
 1) in pleural effusion is a reliable diagnostic marker
for MPM (Petterson et al, 1988; Welker et al, 2007). The pleural
effusions of half of the MPM patients (Y2, Y6, Y7, and G2)
contained 4100mgml
 1 of hyaluronic acid (Table 1). There was
no correlation between intelectin-1 concentration and hyaluronic
acid concentration in the pleural effusions of MPM patients
(Table 1) or other diseases (data not shown). These results
suggested that a high concentration of intelectin-1
(43000ngml
 1) in pleural effusion can be used as another
marker for the clinical diagnosis of MPM.
DISCUSSION
Hyaluronic acid (Petterson et al, 1988; Welker et al, 2007) and
soluble mesothelin (Maeda and Hino, 2006) have been known as
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Figure 3 Immunohistochemistry of intelectin-1 in MPM. Specimens of pleural biopsy were analysed by immunohistochemistry. Patients Y1, Y2, Y4, Y5, Y6,
Y7, and G1 are identical to the ones in Table 1, respectively. Photographs were taken with a  10 (panel C)o r 40 (others) objective lens. A scale bar is
shown in the bottom side of each panel, representatively. (Aa) Haematoxylin–eosin (HE) staining of a specimen of an epithelioid-type MPM patient
(P1-Ep). (Ab) Calretinin staining of MPM in the same specimen. (Ac) Intelectin-1 (ITLN1) staining of MPM in the same specimen with 15:3G9. (Ad) ITLN1
staining of MPM in the same specimen with anti-intelectin pAb. (Ae–Al) ITLN1 staining of MPM in eight epithelioid-type MPM patients (P2-Ep, P3-Ep, Y1,
Y2, Y4, Y6, Y7, or G1) with 15:3G9 (Ae–Ak) or anti-intelectin pAb (Al). (Ba) ITLN1 staining of pleural surface MPM in an epithelioid-type MPM patient
(Y5). (Bb) Calretinin staining of reactive mesothelial cells on a pleura invaded by lung adenocarcinoma in a lung cancer patient (LC). (Bc) No staining of the
pleural cells in the same specimen with 15:3G9. (Bd) TTF-1 staining of pleura-invading lung adenocarcinoma in the same specimen. The arrows indicate
the lung adenocarcinomas invading the pleura. (C) ITLN1 staining in a biphasic-type MPM patient (Bi). ITLN1 was stained with 15:3G9 in epithelioid-like
MPMs in the left side, but not sarcomatoid-like MPMs in the centre and right side. (Da) ITLN1 staining of normal colonic goblet cells. (Db) No staining of
colon adenocarcinoma in the identical patient (CC) with anti-intelectin pAb.
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sdiagnostic markers for MPM in pleural effusion and plasma,
respectively. High concentration of hyaluronic acid (4100mgml
 1)
in the pleural effusion is a reliable marker for MPM (Petterson et al,
1988; Welker et al, 2007). However, in many clinical cases, the
only measurement of hyaluronic acid is insufficient for definite
diagnosis of MPM because many MPMs have pleural effusions with
less hyaluronic acid. Mesothelin is a glycosylphosphatidylinositol-
anchored membrane protein expressed on mesothelial cells (Maeda
and Hino, 2006). The concentration of soluble mesothelin antigen
rises in the serum of epithelioid-type MPM patients (Robinson et al,
2003). Although a truncating variant and proteolytic peptides have
been reported as soluble mesothelin, most soluble mesothelin would
be the digested mesothelin shed from the cell surface rather than the
truncating variant (Segawa et al, 2008). The proteolytic sensitivity
of mesothelin may be an obstacle to reproducibly quantifying
mesothelin. Therefore, mesothelin would be an unsuitable diag-
nostic marker in an accumulative pleural effusion. In this study,
we showed that mesothelioma cells specifically secreted intelectin-1
and that the pleural effusions of MPM patients contained large
amounts of intelectin-1. Intelectin-1 was not proteolysed at 371C
for 24h in plasma or pleural effusion (Supplementary Table 2).
Thus, intelectin-1 in pleural effusion could be used as a specific and
stable diagnostic marker for MPM.
In pleural biopsy-resected tissue, epithelioid-type MPM – but
neither pleura-invading lung adenocarcinomas nor reactive
mesothelial cells near the lung adenocarcinomas – specifically
expressed intelectin-1 protein (Figure 3). In a biphasic-type MPM,
only epithelioid-like mesothelioma cells expressed intelectin-1
(Figure 3C). Intelectin-1 expression in epithelioid-type MPMs near
a pleura surface would be a suitable effect for the intelectin-1
secreted into the pleural cavity. It is often difficult to discriminate
noninvasive MPM cells on a pleura surface from pleura-invading
lung adenocarcinoma or reactive mesothelial cells because these
cells resemble each other in morphology and/or immunohistology
(Kitazume et al, 2000). For example, calretinin was detected in
both reactive mesothelial cells and epithelioid-type MPM cells
(Figure 3Bb and Ab). On the other hand, intelectin-1 was not
expressed in either reactive mesothelial cells or pleura-invading
lung adenocarcinoma (Figure 3Bc). Although additional investi-
gation in reactive mesothelial cells in other diseases than
carcinomatous pleuritis is required, the immunohistochemistry
with anti-intelectin-1 may be useful for differential diagnosis of
epithelioid-type MPM.
Intelectin expression increases during gastrointestinal
infection (Datta et al, 2005; French et al, 2008). Human intestinal
intelectin-1 was produced from goblet cells and secreted into
mucus (Figure 3Da). In opposition to MPM, colon adenocarcino-
ma cells lost expression of intelectin-1 (Figure 3Db), and the
Caco-2 colon adenocarcinoma cell lines did not secrete intelectin-1
(Figure 2A). Thus, the amount of intelectin-1 in a body would
not increase because of colon cancer. It was also reported that
intelectin-1 was related to chronic obstructive pulmonary
disease (Carolan et al, 2008) and asthma (Kuperman et al, 2005).
Pleural effusion with pleuropneumonia tended to contain a
little more intelectin-1 than that with lung cancer (Figure 5B).
Thus, intelectin-1 may be induced in mesothelial cells by an
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Figure 4 Western blotting of intelectin-1 in pleural effusion and plasma.
Recombinant intelectin-1 (rITLN1) is used as a positive control.
Mesothelioma patients of Y1, Y2, Y4, Y5, Y6, Y7, and G1 are identical to
the ones in Table 1, respectively. (A) Plasma (0.5ml) was analysed by
non-reducing western blotting using affinity-purified anti-intelectin pAb.
(B) Pleural effusion (0.5ml) was analysed by non-reducing western blotting
using affinity-purified anti-intelectin pAb or 15:3G9. Results were obtained
by reprobing and reblotting of an identical membrane as described in the
Materials and Methods.
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Figure 5 Concentration of intelectin-1 in pleural effusion and plasma.
Intelectin-1 concentration was measured by sandwich ELISA as described in
the Materials and Methods. Values represent the mean of duplicate
determinations. The bold horizontal bar is the mean value of each sample.
(A) Intelectin-1 concentration in heparinised plasmas of normal healthy
donors (NH) or MPM patients (MPM). (B) Intelectin-1 concentration in
heparinised pleural effusions of patients with MPM (MPM), lung cancer
(LC), tuberculosis (TB), and pleuropneumonia (PP). Lung cancer contains 9
adenocarcinomas, 2 small cell carcinomas (intelectin-1 concentration, 1359
and 98ngml
 1), and 1 large cell carcinoma (intelectin-1 concentration,
222ngml
 1). Differences in mean values were evaluated by permutation
tests. The P-value between MPM and LC was 0.0117. The P-value between
MPM and PP was 0.0306.
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sinflammatory stimulation, such as Th2 cytokine, and function as a
host defence protein in relation to a respiratory inflammation.
Asbestos induces pleural inflammation (Kroegel and Antony,
1997). Furthermore, it was reported that asbestos directly induced
intelectin-1-expression in mesothelial cells (Wali et al, 2005). To
analyse the neoplastic transformation mechanism of mesothelial
cells expressing intelectin-1, it may be useful to investigate further
what stimulation, including asbestos, induces expression of
intelectin-1 in mesothelial cells.
Intelectin-1 of ACC-MESO-1 was not identified by western
blotting using 15:3G9 despite its detection with other mAbs against
intelectin-1 (Figure 2A). This result suggests that intelectin-1 of
ACC-MESO-1 lacks an epitope of 15:3G9 in the N-terminus
of serum intelectin-1. The intelectin-1 of ACC-MESO-1 had
neither single-nucleotide polymorphisms nor obvious shift in
electrophoretic mobility in comparison with the intelectin-1 of
ACC-MESO-4 that was detectable with 15:3G9 (see Results section
and Figure 2A). Furthermore, an unglycosylated mutant of
intelectin-1 was also recognised with 15:3G9 (Supplementary
Table 1). Thus, intelectin-1 of ACC-MESO-1 would have neither
long deletion of the N-terminus nor deficiency of N-linked
glycosylation. These results suggest that intelectin-1 of ACC-MESO-1
does not have a 15:3G9-recognised post-translational modification
of normal serum intelectin-1. Shortly, we would analyse the
epitope of 15:3G9 and the post-translational modification of
intelectin-1 because the rate of this modification might vary with
a disease such as MPM.
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